Hua Gu
Gu_hua@mail.tongji.edu.cn
Chinese, English
Shanghai
Tongji University
Life Sciences
  • 1997 - Bachelor of Science in Biochemistry from East China University of Science and Technology
  • 2002 - Master's degree in Biochemistry and Molecular Biology from Fudan University
  • 2009 - PhD in Biomedical Engineering from Tongji University
  • Postdoctoral research at Louisiana State University Health Sciences Center, USA (2009-2011)
  • 2004 - Present: Tongji University, School of Life Sciences and Technology, Lecturer
  • 2020-2021: Advanced Individual in Undergraduate Enrollment Work, Tongji University
  • 2021: Advanced Individual in Women's Work, Tongji University
  • 2019: Model Family Award, Tongji University
  • 2019: Third Prize in Teaching Achievement, Tongji University
  • 2017: Talent Fund for Female Teachers, Tongji University
  • 2017: Second Prize in Teaching Achievement, Tongji University
  • 2014: First Prize in Teaching Achievement, Shanghai
  • 2014: Advanced Class Teacher, Tongji University
  • 2013: Outstanding Contribution Award for Class Teachers, Tongji University
  • 2011: Excellent Teacher in Military Training, Tongji University
  • 2012: Third Prize in Young Teachers' Teaching Competition, School of Life Sciences and Technology
  • 2009: First Prize in Young Teachers' Teaching Competition, School of Life Sciences and Technology
Antitumor and autoimmune disease biopharmaceutical development
Molecular regulation of tumor angiogenesis
  • Reversing PD-1 Resistance in B16F10 Cells and Recovering Tumour Immunity Using a COX2 Inhibitor, Hua Gu* and Jianmin Fang*, 2022
  • A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity, Hua Gu* and Jianmin Fang*, 2022
  • Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression, Hua Gu*, Jianmin Fang *, 2021
  • A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation, Hua Gu*, Jianmin Fang *, 2021
  • Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody, Hua Gu*, Jianmin Fang*, 2020
  • Improved recombinant protein production by regulation of transcription and protein transport in Chinese hamster ovary cells, Hua Gu, Jianmin Fang*, 2019
  • CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy, Hua Gu* , Jianmin Fang*, 2018
  • Protein phosphatase-1 inhibitor-2 is a novel memory suppressor, Hua Gu, Angus C Nairn, Ya-Ping Tang, Paul J. Colombo, Houhui Xia, 2015
  • cAMP/PKA pathways and S56 phosphorylation are involved in AA/PGE2-induced increases in rNaV1.4 current, Hua Gu*, Yan-Jia Fang, dong-dong Liu, Ping Chen, Yan-Ai Mei*, 2015
  • The Rac1 inhibitor NSC23766 suppresses CREB signaling by targeting NMDA receptor function, Hua Gu, Benjamin A.Siddoway, Benjamin J. Hall, Pablo E. Castillo, Houhui Xia, 2014
  • Modulation of muscle rNa V1.4 Na+ channel isoform by arachidonic acid and its non-metabolized analog, Gu, H.Fang, Y. J.He, Y. L.Sun, J.Zhu, J.Mei, Y. A., 2009
Biopharmaceuticals Antitumor Autoimmune Diseases Drug Development Molecular Biology Angiogenesis Tumor Regulation Molecular Mechanisms Therapeutics

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.